Up-regulation in expression of vesicular glutamate transporter 3 in substantia nigra but not in striatum of 6-hydroxydopamine-lesioned rats

NeuroSignals

Volumn 15, Issue 5, 2007, Pages 238-248

  Chung, E K Y ^a   Chen, L W ^b   Chan, Y S ^c   Yung, K K L ^a  

^a HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Animal model of Parkinson's disease; Basal ganglia; Degeneration of dopaminergic neurons; Neurotoxin; Vesicular glutamate transporters

Indexed keywords

4 AMINOBUTYRIC ACID; OXIDOPAMINE; VESICULAR GLUTAMATE TRANSPORTER 1; VESICULAR GLUTAMATE TRANSPORTER 2; VESICULAR GLUTAMATE TRANSPORTER 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; FEMALE; IMMUNOCYTOCHEMISTRY; IMMUNOREACTIVITY; NERVE CELL; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PROTEIN EXPRESSION; RAT; SUBSTANTIA NIGRA; UPREGULATION;

EID: 34547956841     PISSN: 1424862X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000101704     Document Type: Article

References (48)

1. Aihara Y, Mashima H, Onda H, Hisano S, Kasuya H, Hori T, Yamada S, Tomura H, Yamada Y, Inoue I, Kojima I, Takeda J: Molecular cloning of a novel brain-type Na(+)-dependent inorganic phosphate cotransporter. J Neurochem 2000;74:2622-2625.
2. Albin RL, Young AB, Penney JB: The functional anatomy of basal ganglia disorders. Trends Neurosci 1989;12:366-375.
3. Albin RL, Young AB, Penney JB: The functional anatomy of disorders of the basal ganglia. Trends Neurosci 1995;18:63-64.
4. Bai L, Xu H, Collins JF, Ghishan FK: Molecular and functional analysis of a novel neuronal vesicular glutamate transporter. J Biol Chem 2001;276:36764-36769.
5. Bellocchio EE, Reimer RJ, Fremeau RT Jr, Edwards RH: Uptake of glutamate into synaptic vesicles by an inorganic phosphate transporter. Science 2000;289:957-960.
6. Blandini F, Greenamyre JT, Nappi G: The role of glutamate in the pathophysiology of Parkinson's disease. Funct Neurol 1996;11:3-15.
7. Blandini F, Porter RH, Greenamyre JT: Glutamate and Parkinson's disease. Mol Neurobiol 1996;12:73-94.
8. Bolam JP, Bennett BD: Microcircuitry of the neostriatum;in Ariano MA, Surmeier PJ (eds): Molecular and Cellular Mechanisms of Neostriatal Function. Austin, Landes Company, 1995, pp 1-19.
9. Bolam JP, Hanley JJ, Booth PA, Bevan MD: Synaptic organisation of the basal ganglia. J Anat 2000;196:527-542.
10. Calabresi P, Mercuri NB, Sancesario G, Bernardi G: Electrophysiology of dopamine-denervated striatal neurons. Implications for Parkinson's disease. Brain 1993;116:433-452.
11. Danbolt NC: Glutamate uptake. Prog Neurobiol 2001;65:1-105.
12. Daniels RW, Collins CA, Gelfand MV, Dant J, Brooks ES, Krantz DE, DiAntonio A: Increased expression of the Drosophila vesicular glutamate transporter leads to excess glutamate release and a compensatory decrease in quantal content. J Neurosci 2004;24:10466-10474.
13. DeLong MR: Primate models of movement disorders of basal ganglia origin. Trends Neurosci 1990;13:281-285.
14. Fremeau RT Jr, Troyer MD, Pahner I, Nygaard GO, Tran CH, Reimer RJ, Bellocchio EE, Fortin D, Storm-Mathisen J, Edwards RH: The expression of vesicular glutamate transporters defines two classes of excitatory synapse. Neuron 2001;31:247-260.
15. Gras C, Herzog E, Bellenchi GC, Bernard V, Ravassard P, Pohl M, Gasnier B, Giros B, El Mestikawy S: A third vesicular glutamate transporter expressed by cholinergic and serotoninergic neurons. J Neurosci 2002;22:5442-5451.
16. Greenamyre JT: Glutamate-dopamine interactions in the basal ganglia: relationship to Parkinson's disease. J Neural Transm Gen Sect 1993;91:255-269.
17. Greenamyre JT: Glutamatergic influences on the basal ganglia. Clin Neuropharmacol 2001;24:65-70.
18. Herzog E, Bellenchi GC, Gras C, Bernard V, Ravassard P, Bedet C, Gasnier B, Giros B, El Mestikawy S: The existence of a second vesicular glutamate transporter specifies subpopulations of glutamatergic neurons. J Neurosci 2001;21:RC181.
19. Hisano S, Nogami H: Transporters in the neurohypophysial neuroendocrine system, with special reference to vesicular glutamate transporters (BNPI and DNPI): a review. Microsc Res Tech 2002;56:122-131.
20. Jabaudon D, Shimamoto K, Yasuda-Kamatani Y, Scanziani M, Gahwiler BH, Gerber U: Inhibition of uptake unmasks rapid extracellular turnover of glutamate of nonvesicular origin. Proc Natl Acad Sci USA 1999;96:8733-8738.
21. Kaneko S, Hikida T, Watanabe D, Ichinose H, Nagatsu T, Kreitman RJ, Pastan I, Nakanishi S: Synaptic integration mediated by striatal cholinergic interneurons in basal ganglia function. Science 2000;289:633-637.
22. Lau WK, Lui PW, Wong CKC, Chan YS, Yung KKL: Differential expression of N-methyl-D-aspartate receptor subunit messenger ribonucleic acids and immunoreactivity in the rat neostriatum during postnatal development. Neurochem Int 2003;43:47-65.
23. Lau WK, Yung WH, Chan YS, Yung KKL: Developmental assembly of GABA receptors in the rat substantia nigra;in Magill PJ, Bolam JP (eds): Basal Ganglia VIII. New York, Springer, 2005, pp 229-240.
24. Lin LH, Talman WT: Nitroxidergic neurons in rat nucleus tractus solitarii express vesicular glutamate transporter 3. J Chem Neuroanat 2005;29:179-191.
25. Lui PW, Yeung CW, Yung WH, Shi Y, Chen LW, Chan YS, Yung KKL: Ablation of gene expression of N-methyl-D-aspartate receptor one by antisense oligonucleotides in striatal neurons in culture. Neurosignals 2005;14:303-316.
26. Naito S, Ueda T: Characterization of glutamate uptake into synaptic vesicles. J Neurochem 1985;44:99-109.
27. BR2 receptor immunoreactivity in neurochemically identified neurons of the rat neostriatum. J Comp Neurol 2001;433:458-470.
28. Ni B, Wu X, Yan GM, Wang J, Paul SM: Regional expression and cellular localization of the Na(+)-dependent inorganic phosphate cotransporter of rat brain. J Neurosci 1995;15:5789-5799.
29. Nickerson PA, Guerci A, El Mestikawy S, Semba K: Vesicular glutamate transporter 3 immunoreactivity is present in cholinergic basal forebrain neurons projecting to the basolateral amygdala in rat. J Comp Neurol 2006;498:690-711.
30. Onn SP, West AR, Grace AA: Dopamine-mediated regulation of striatal neuronal and network interactions. Trends Neurosci 2000;23:S48-S56.
31. Ozkan ED, Ueda T: Glutamate transport and storage in synaptic vesicles. Jpn J Pharmacol 1998;77:1-10.
32. Paxinos P, Watson C: The Rat Brain in Stereotaxic Coordinates, ed 2. New York, Academic Press, 1986.
33. Pothos EN, Larsen KE, Krantz DE, Liu Y, Haycock JW, Setlik W, Gershon MD, Edwards RH, Sulzer D: Synaptic vesicle transporter expression regulates vesicle phenotype and quantal size. J Neurosci 2000;20:7297-7306.
34. Robelet S, Melon C, Guillet B, Salin P, Kerkerian-Le Goff L: Chronic L-DOPA treatment increases extracellular glutamate levels and GLT1 expression in the basal ganglia in a rat model of Parkinson's disease. Eur J Neurosci 2004;20:1255-1266.
35. Rodriguez MC, Obeso JA, Olanow CW: Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann Neurol 1998;44:S175-S188.
36. Schafer MK, Varoqui H, Defamie N, Weihe E, Erickson JD: Molecular cloning and functional identification of mouse vesicular glutamate transporter 3 and its expression in subsets of novel excitatory neurons. J Biol Chem 2002;277:50734-50748.
37. Seal RP, Edwards RH: The diverse roles of vesicular glutamate transporter 3. Handb Exp Pharmacol 2006;137-150.
38. Smith Y, Bevan MD, Shink E, Bolam JP: Microcircuitry of the direct and indirect pathways of the basal ganglia. Neuroscience 1998;86:353-387.
39. Stornetta RL, Rosin DL, Simmons JR, McQuiston TJ, Vujovic N, Weston MC, Guyenet PG: Coexpression of vesicular glutamate transporter-3 and gamma-aminobutyric acidergic markers in rat rostral medullary raphe and intermediolateral cell column. J Comp Neurol 2005;492:477-494.
40. Sze SCW, Wong CKC, Yung KKL: Modulation of the gene expression of N-methylD-aspartate receptor NR2B in the rat neostriatum by a single dose of specific antisense oligodeoxynucleotide. Neurochem Int 2001;39:319-327.
41. Takamori S, Malherbe P, Broger C, Jahn R: Molecular cloning and functional characterization of human vesicular glutamate transporter 3. EMBO Rep 2002;3:798-803.
42. Takamori S, Rhee JS, Rosenmund C, Jahn R: Identification of a vesicular glutamate transporter that defines a glutamatergic phenotype in neurons. Nature 2000;407:189-194.
43. Takamori S, Rhee JS, Rosenmund C, Jahn R: Identification of differentiation-associated brain-specific phosphate transporter as a second vesicular glutamate transporter (VGLUT2). J Neurosci 2001;21:RC182.
44. Ungerstedt U: 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur J Pharmacol 1968;5:107-110.
45. Ungerstedt U, Ljungberg T, Steg G: Behavioral, physiological, and neurochemical changes after 6-hydroxydopamine-induced degeneration of the nigro-striatal dopamine neurons. Adv Neurol 1974;5:421-426.
46. Varoqui H, Schafer MK, Zhu H, Weihe E, Erickson JD: Identification of the differentiation-associated Na + /PI transporter as a novel vesicular glutamate transporter expressed in a distinct set of glutamatergic synapses. J Neurosci 2002;22:142-155.
47. Wojcik SM, Rhee JS, Herzog E, Sigler A, Jahn R, Takamori S, Brose N, Rosenmund C: An essential role for vesicular glutamate transporter 1 (VGLUT1) in postnatal development and control of quantal size. Proc Natl Acad Sci USA 2004;101:7158-7163.
48. Yamada M, Oligino T, Mata M, Goss JR, Glorioso JC, Fink DJ: Herpes simplex virus vector-mediated expression of Bcl-2 prevents 6-hydroxydopamine- induced degeneration of neurons in the substantia nigra in vivo. Proc Natl Acad Sci USA 1999;96:4078-4083.